Stay Informed about the latest news on PEMAZYRE®

Sign up to receive updates from Incyte

Stay up to date with the latest news on PEMAZYRE^®▼ (pemigatinib).

Please complete the form below to receive relevant information from Incyte, such as further information on PEMAZYRE and treatment of cholangiocarcinoma (CCA).

Fields marked with an * are mandatory.

Please check the boxes below before proceeding with submitting your information:

I have read and acknowledge Incyte’s Privacy Policy and Legal Notices.*

I certify that I am a licensed healthcare professional practising medicine in Switzerland.*

I wish to receive e-mail communications from Incyte containing information and education relevant to my clinical practice, including disease and/or diagnostics educational material and marketing materials pertaining to Incyte medicinal products. I understand that I have the option to opt-out from receiving these emails at any time using contact details that will be provided to me with each e-mail communication or by emailing privacy@incyte.com.

Incyteful for you

An Incyte platform that offers medical education relevant to your daily practice. Easy to access, personalised content that fits with your schedule.

Incyteful is your one-stop resource for updates about the disease areas and Incyte's approved products that you care about.

Coming soon

PEMAZYRE self-directed learning

A self-directed learning material to complete in your own time. With the PEMAZYRE learning module, you can learn about the unmet needs in CCA, discuss the need for molecular profiling for early patient identification and learn more about PEMAZYRE.

Learn about PEMAZYRE

Stay informed

Sign up to receive updates from Incyte

Registration created successfully

Something went wrong

Incyteful for you

PEMAZYRE self-directed learning

External link disclaimer